Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tributyrin Supplementation in Parkinson Disease
NCT05446168Phase 1Terminated
- Start
- Jul 2022
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of tributyrin in Parkinson's disease (PD) (2 arms). Primary endpoints: Whole Brain Butyrate PET Radiotracer Binding at 30 days and Glucose Metabolism at 30 days. Started Jul 2022; status: terminated.
02
Drugs
tributyrin
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT05446168.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05446168.